TORONTO--(BUSINESS WIRE)--Ontario Bioscience Innovation Organization (“OBIO®”), a non-profit organization that is Ontario’s leading advocate for the life science sector, announces the election of four new members to its Board of Directors: Shelley Boyd, Jeremy Bridge-Cook, Michael Cloutier and Cathy Szabo.
“OBIO is delighted to welcome four new Directors to the Board,” said Dr. David Young, Chair of the Board of Directors. “Their range of experiences and expertise will both complement and augment the group of thought leaders OBIO has brought to the table to build a sustainable biosciences sector that creates jobs, attracts expertise and ideas, elevates health outcomes and builds a more prosperous economy.”
“OBIO’s Board is an integral part of the advocacy, sector promotion and strategic leadership work that we do.” said Gail Garland, President and Chief Executive Officer of OBIO. “I and the rest of the OBIO team are looking forward to the support and contributions of this impressive group as we move forward building companies, the industry and an industry friendly environment.”
OBIO is also pleased to announce that Jung-Kay Chiu, Partner, Norton Rose Fulbright, will continue to serve as Secretary for the OBIO Board of Directors and that Prabh Bob Singh, Partner PWC will continue as Treasurer.
Michael Cloutier, Director and Vice Chair
Michael Cloutier
is CEO, PTC Therapeutics and an Executive Leader & Human Resources
Strategist with demonstrated success at national and global levels
within the Pharmaceutical, Biotech and Health Sciences industries. Mr.
Cloutier has identified, initiated and created strategic plans for
organizational transformation and performance enhancement. He delivers
results through building and maintaining strong relationships internally
and externally across all stakeholder populations. Michael is recognized
as a focused and ethical leader who demonstrates linear and abstract
thinking to meet and exceed the needs of an organization.
Jeremy Bridge-Cook, Director
Dr. Bridge-Cook was named
Senior Vice President of Research and Development of Luminex in May
2012. Previously he served as Senior Vice President of the Assay Group
and Vice President, Luminex Molecular Diagnostics. He also served at Tm
Bioscience, which became Luminex Molecular Diagnostics following the
acquisition of Tm Bioscience by Luminex in March 2007. Dr. Bridge-Cook
joined Tm Bioscience in July 2000 as Director of Business Development
and served in various capacities thereafter, including Vice President of
Business Development, Vice President of Marketing & Business
Development, and Senior Vice President of Corporate Development. Prior
to joining Tm, Dr. Bridge-Cook worked as a venture capital investment
analyst at MDS Capital Corporation and University Medical Discoveries
Inc. Dr. Bridge-Cook has a Ph.D. in immunology from the University of
Toronto.
Shelley Boyd, Director
Shelley Boyd, MD, FRCSC, is a
clinician-scientist and Ophthalmologist specializing in diseases of the
retina. She trained at the University of Toronto, with fellowships at
Moorfields Eye Hospital, UK and the Scripps Research Institute,
California. She is Assistant Professor of Ophthalmology & Vision
Sciences, with cross-appointment to Laboratory Medicine & Pathobiology,
and Biomedical Engineering, McMaster University. Shelley was formerly
Head of the Ocular Angiogenesis Research Program, worldwide, with
Novartis (Switzerland), overseeing pre-clinical and translational
aspects of the Ranibizumab (Lucentis) program – the standard of care
treatment for “wet” Age Related Macular Degeneration (AMD). She is
President & Chief Scientific Officer of Translatum Medicus inc (TMi), a
spin-off from St Michael’s Hospital, dedicated to saving sight for
patients with “dry” AMD. With a patented lead compound, TMi-018, and a
translational platform, TMi de-risks and accelerates drug development
for dry AMD. Dr. Boyd is director of Canada’s only dedicated High-risk
dry AMD Clinic.
Cathy Szabo, Director
Cathy Szabo is the President & Chief
Executive Officer of Providence Care, the leading provider of Aging,
Mental Health and Rehabilitative care in southeastern Ontario. In her
over 30 years of experience, Cathy has focused on Health System
Improvement, creating organizational cultures of quality and excellence
while delivering patient care that meets individual’s needs. Under her
leadership, Central CCAC developed a Medication Management Support
Services program which was awarded Best Innovation Healthcare Practice
in Canada by the National Research Corporation (NRC). Additionally, this
program was recognized at the bronze level by the Institute for Public
Administration of Canada (IPAC).
A dedicated advocate for healthcare, Cathy is an active member of the Knowledge Exchange Board, Canadian Patient Safety Institute; the International Society for Quality in Health Care; Centre for Health System Design and Management, Conference Board of Canada; Osgoode Hall Health Law Program; and GS1 Canada Health Care Advisory Council. In addition, Cathy is the Chair of Healthcare Insurance Reciprocal of Canada (HIROC). Throughout her career, Cathy has successfully delivered cost-effective models of care by applying evidence-based leading practices from around the globe to service delivery in Ontario. Cathy holds a Master of Public Health, a Bachelor of Science in Nursing degree and a diploma of Clinical Administration from the Ontario Hospital Association. She is a Registered Nurse and a Certified Health Executive with the Canadian College of Health Leaders.
About the Ontario Bioscience Innovation Organization
The
Ontario Bioscience Innovation Organization (OBIO®) is a not-for-profit,
membership-based organization engaged in the development of an
integrated health innovation economy for Ontario and one that will
become a global leader in providing health technology products and
services to the international marketplace. OBIO advances this goal
through advocacy, promotion and strategic leadership and via
collaborative partnerships with industry, academia, patients and
government. For more information, visit the OBIO website www.obio.ca
and follow OBIO on Twitter @OntBioscience.
